Existing backers also bought in, including Bristol Myers Squibb, Eli Lilly, Pfizer Ventures ... with backup from RiverVest Venture Partners, Red Tree Venture Capital, abrdn, Ysios Capital ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...

Shares of Eli Lilly & Co. LLY rallied 3.26% to $864.90 Monday, on what proved to be an all-around great trading session for ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target ...

We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher In this article, we are ...

Zepbound is Eli Lilly's biggest growth driver at the moment, but it isn't the only drug pushing total sales higher for this well-established pharmaceutical giant. Its fourth-quarter revenue not ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.

Eli Lilly's MounjaroNow, Eli Lilly, the largest pharmaceutical company in the world in terms of market capitalisation, has ...

Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer ...